CRISPR Therapeutics AG
For the period ended Dec 31, 2024. Filed Feb 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 11, 2025
CRSP$50.04-0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Shareholders' Equity
(In thousands, except share and per share data)
| Common Shares · Treasury Shares · Additional | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | CHF 0.03Par Value | Shares | Amount,at cost | Paid-inCapital | AccumulatedDeficit | AccumulatedOtherComprehensive(Loss) Income | Total Shareholders' Equity | |
| Balance at December 31, 2021 | 76,990,066 | $2,391 | 180,316 | $(63) | $2,598,114 | $(195,915) | $(5,067) | $2,399,460 |
| Issuance of common shares | 12,365 | — | — | — | 970 | — | — | 970 |
| Vesting of restricted shares | 237,932 | 8 | — | — | — | — | — | 8 |
| Exercise of vested options, net of issuance costs of $0.9 million | 1,235,528 | 42 | — | — | 35,771 | — | — | 35,813 |
| Purchase of common stock under ESPP | 36,559 | — | — | — | 2,036 | — | — | 2,036 |
| Stock-based compensation expense | — | — | — | — | 97,947 | — | — | 97,947 |
| Other comprehensive loss | — | — | — | — | — | — | (10,580) | (10,580) |
| Net loss | — | — | — | — | — | (650,175) | — | (650,175) |
| Balance at December 31, 2022 | 78,512,450 | $2,441 | 180,316 | $(63) | $2,734,838 | $(846,090) | $(15,647) | $1,875,479 |
| Issuance of common shares, net of issuance costs of $2.9 million | 458,547 | 15 | — | — | 32,379 | — | — | 32,394 |
| Vesting of restricted shares | 277,808 | 10 | — | — | — | — | — | 10 |
| Exercise of vested options, net of issuance costs of $0.5 million | 742,291 | 31 | (10,000) | 1 | 28,071 | — | — | 28,103 |
| Purchase of common stock under ESPP | 53,282 | — | — | — | 1,839 | — | — | 1,839 |
| Stock-based compensation expense | — | — | — | — | 81,028 | — | — | 81,028 |
| Other comprehensive income | — | — | — | — | — | — | 17,560 | 17,560 |
| Net loss | — | — | — | — | — | (153,610) | — | (153,610) |
| Balance at December 31, 2023 | 80,044,378 | $2,497 | 170,316 | $(62) | $2,878,155 | $(999,700) | $1,913 | $1,882,803 |
| Issuance of common shares, net of issuance costs of $4.0 million | 4,309,521 | 145 | — | — | 297,557 | — | — | 297,702 |
| Vesting of restricted shares | 450,701 | 16 | — | — | — | — | — | 16 |
| Exercise of vested options, net of issuance costs of $0.8 million | 900,136 | 40 | — | — | 29,539 | — | — | 29,579 |
| Purchase of common stock under ESPP | 37,245 | — | — | — | 1,738 | — | — | 1,738 |
| Stock-based compensation expense | — | — | — | — | 86,567 | — | — | 86,567 |
| Other comprehensive loss | — | — | — | — | — | — | (73) | (73) |
| Net loss | — | — | — | — | — | (366,252) | — | (366,252) |
| Balance at December 31, 2024 | 85,741,981 | 2,698 | 170,316 | (62) | 3,293,556 | (1,365,952) | 1,840 | 1,932,080 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.